MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
Neovasc Revenue 2011-2026 | NVCN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Neovasc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.55 M | 1.96 M | 2.09 M | 1.75 M | 5.39 M | 9.51 M | 9.93 M | 13.7 M | 11 M | 7.86 M | 5.15 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.7 M | 1.75 M | 6.44 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.35 | - | $ 21.8 M | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Orthofix Medical
OFIX
|
822 M | $ 11.72 | -1.26 % | $ 464 M |  Curacao |
 |
LENSAR
LNSR
|
53.5 M | $ 5.56 | -8.4 % | $ 64 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
AxoGen
AXGN
|
225 M | $ 32.61 | 2.71 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 36.56 | -0.19 % | $ 1.13 B | USA |
 |
Penumbra
PEN
|
1.4 B | $ 334.17 | -0.41 % | $ 13 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Electromed
ELMD
|
64 M | $ 24.7 | 0.86 % | $ 209 M | USA |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 225.5 | -0.7 % | $ 15.9 B | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.7 | 3.3 % | $ 38.1 M | USA |
 |
Aethlon Medical
AEMD
|
574 K | $ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
Profound Medical Corp.
PROF
|
7.2 M | $ 5.15 | -4.63 % | $ 180 M |  Canada |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Quanterix Corporation
QTRX
|
139 M | $ 3.82 | -3.05 % | $ 163 M | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 11.48 | 10.7 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
40.9 M | $ 0.7 | -1.83 % | $ 29.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
1.3 M | $ 2.4 | -1.64 % | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.91 | 4.83 % | $ 146 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.91 | -3.4 % | $ 373 M | USA |
 |
Outset Medical
OM
|
119 M | $ 3.53 | -2.35 % | $ 53.7 K | USA |
 |
Inspire Medical Systems
INSP
|
912 M | $ 52.07 | -0.17 % | $ 1.53 B | USA |
 |
Sintx Technologies
SINT
|
1.02 M | $ 2.57 | 0.78 % | $ 7.13 M | USA |
 |
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.31 | -5.76 % | $ 53.3 M | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Sensus Healthcare
SRTS
|
27.5 M | $ 3.96 | -3.65 % | $ 64.7 M | USA |
 |
InspireMD
NSPR
|
8.98 M | $ 1.79 | 3.47 % | $ 115 M | Israel |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |